ADC Therapeutics (NYSE:ADCT – Get Free Report) is expected to be announcing its earnings results before the market opens on ...

Rhumbline Advisers lifted its holdings in ADC Therapeutics SA (NYSE:ADCT – Free Report) by 15.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its ...

ADC Therapeutics SA’s ADCT share price has surged by 11.39%, which has investors questioning if this is right time to sell.

Do the numbers hold clues to what lies ahead for the stock? ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

Frazier Life Sciences launched Callio Therapeutics, a cancer startup headquartered in Seattle and Singapore. Frazier led ...

Callio Therapeutics fired out of the gate earlier ... Callio is focused on antibody-drug conjugates (ADC), a combination of targeted therapy and chemotherapy that attacks cancer cells without ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...